IP Library Granted Patent US 9,040,485
Granted Patent B2
US 9,040,485 · App. 13/651,884 · Granted May 26, 2015

Synthetic analogues of neural regeneration peptides

Inventors: Paul William Richard Harris (Waitakere, NZ); Margaret Ann Brimble (Auckland, NZ); Frank Sieg (Auckland, NZ)
Assignee: CURONZ HOLDINGS COMPANY LIMITED
C07K7/08G01N2800/2878G01N2800/2892G01N2800/2835G01N2800/28G01N2800/285A61K38/00C07K14/48C07K7/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,485
App. No.
13/651,884
Granted
May 26, 2015
Kind
B2
Abstract

Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizaing β-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.

Claims (3)

1. A method for the treatment of peripheral neuropathy, multiple sclerosis and amyotrophic lateral sclerosis in an animal, comprising administering to said animal a pharmaceutically effective amount of a neural regeneration peptide (NRP) compound comprising an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, or a pharmaceutical composition comprising a NRP compound comprising an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 and a pharmaceutically acceptable excipient.

2. The method of claim 1 , wherein said NRP compound consists of the sequence SEQ ID NO:5.

3. The method of claim 1 , wherein said NRP compound consists of the sequence SEQ ID NO:6.

Continuity (5)
Continuation 12754937 · Apr 6, 2010
Continuation PCTUS2008011951 · Oct 17, 2008
Provisional Application 60999292 · Oct 17, 2007
Provisional Application 60999503 · Oct 18, 2007
Related Publication 20130231289A1 · Sep 5, 2013